statement_id,standardized_cancer,raw_cancer,modified_standardized_cancer,biomarker,therapy
0,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Tamoxifen', 'Abemaciclib']"
1,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Tamoxifen', 'Abemaciclib']"
2,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Tamoxifen', 'Abemaciclib']"
3,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Anastrozole', 'Abemaciclib']"
4,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Anastrozole', 'Abemaciclib']"
5,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Anastrozole', 'Abemaciclib']"
6,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Abemaciclib', 'Letrozole']"
7,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Abemaciclib', 'Letrozole']"
8,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Abemaciclib', 'Letrozole']"
9,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Abemaciclib']"
10,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Abemaciclib']"
11,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Abemaciclib']"
12,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']",['Abemaciclib']
13,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']",['Abemaciclib']
14,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']",['Abemaciclib']
15,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BARD1 oncogenic variants'],"['Prednisone', 'Niraparib', 'Abiraterone acetate']"
16,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRIP1 oncogenic variants'],"['Prednisone', 'Niraparib', 'Abiraterone acetate']"
17,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRIP1 pathogenic variants'],"['Prednisone', 'Niraparib', 'Abiraterone acetate']"
18,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CDK12 pathogenic variants'],"['Prednisone', 'Niraparib', 'Abiraterone acetate']"
19,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['KRAS p.G12C'],['Adagrasib']
20,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],['Trastuzumab emtansine']
21,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],['Trastuzumab emtansine']
22,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR somatic variants'],['Afatinib']
23,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['v::ALK'],['Alectinib']
24,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Alectinib']
25,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Fulvestrant', 'Alpelisib']"
26,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'PIK3CA somatic variants']","['Fulvestrant', 'Alpelisib']"
27,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Fulvestrant', 'Alpelisib']"
28,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 20 (Insertion)'],"['Carboplatin', 'Amivantamab', 'Pemetrexed']"
29,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 20 (Insertion)'],['Amivantamab']
30,APL with PML-RARA,low-risk acute promyelocytic leukemia (APL),low-risk apl with pml-rara,['PML::RARA'],['Arsenic trioxide']
31,APL with PML-RARA,acute promyelocytic leukemia (APL),apl with pml-rara,['PML::RARA'],['Arsenic trioxide']
32,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Asciminib']
33,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),philadelphia chromosome-positive chronic myelogenous leukemia,"['ABL1 p.T315I', 'BCR::ABL1']",['Asciminib']
34,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['PD-L1 >= 1%'],['Atezolizumab']
35,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['PD-L1 >= 50%'],['Atezolizumab']
36,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['PD-L1 >= 10% TIIC'],['Atezolizumab']
37,Non-Small Cell Lung Cancer,metastatic non-squamous non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Bevacizumab', 'Atezolizumab']"
38,Non-Small Cell Lung Cancer,metastatic non-squamous non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Atezolizumab']"
39,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR somatic variants'],['Atezolizumab']
40,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Atezolizumab']
41,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Vemurafenib', 'Cobimetinib', 'Atezolizumab']"
42,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Vemurafenib', 'Cobimetinib', 'Atezolizumab']"
43,Gastrointestinal Stromal Tumor,unresectable or metastatic GIST,unresectable or metastatic gastrointestinal stromal tumor,['PDGFRA p.D842V'],['Avapritinib']
44,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Binimetinib', 'Encorafenib']"
45,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Binimetinib', 'Encorafenib']"
46,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['BRAF p.V600E'],"['Binimetinib', 'Encorafenib']"
47,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Abemaciclib', 'Letrozole']"
48,Acute Lymphoid Leukemia,b-cell precursor acute lymphoblastic leukemia (ALL),b-cell precursor acute lymphoid leukemia,['CD19 +'],['Blinatumomab']
49,Acute Lymphoid Leukemia,b-cell precursor acute lymphoblastic leukemia (ALL),b-cell precursor acute lymphoid leukemia,['CD19 +'],['Blinatumomab']
50,Acute Lymphoid Leukemia,b-cell precusor acute lymphoblastic leukemia (ALL),b-cell acute lymphoid leukemia,"['BCR::ABL1', 'CD19 +']",['Blinatumomab']
51,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myelogenous leukemia (CML),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Bosutinib']
52,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myelogenous leukemia (CML),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Bosutinib']
54,Anaplastic Large Cell Lymphoma,"systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified",systemic anaplastic large cell lymphoma,['CD30 +'],"['Doxorubicin', 'Prednisone', 'Brentuximab vedotin', 'Cyclophosphamide']"
55,Anaplastic Large Cell Lymphoma,cutaneous analastplci large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF),cutaneous anaplastic large cell lymphoma,['CD30 +'],['Brentuximab vedotin']
56,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Brigatinib']
57,Adenocarcinoma of the Gastroesophageal Junction,metastatic gastric or gastroesophageal junction adenocarcinoma,metastatic adenocarcinoma of the gastroesophageal junction,['HER2-positive'],['Capecitabine']
58,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Fulvestrant', 'Capivasertib']"
59,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'PIK3CA somatic variants']","['Fulvestrant', 'Capivasertib']"
60,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Fulvestrant', 'Capivasertib']"
61,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['AKT1 somatic variants', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
62,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'AKT1 somatic variants', 'HER2-negative']","['Fulvestrant', 'Capivasertib']"
63,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'AKT1 somatic variants', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
64,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['AKT1 amplification', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
65,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['AKT1 amplification', 'PR positive', 'HER2-negative']","['Fulvestrant', 'Capivasertib']"
66,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['AKT1 amplification', 'PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
67,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN nonsense variants', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
68,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN nonsense variants', 'PR positive', 'HER2-negative']","['Fulvestrant', 'Capivasertib']"
69,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN nonsense variants', 'PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
70,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN frameshift variants', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
71,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN frameshift variants', 'PR positive', 'HER2-negative']","['Fulvestrant', 'Capivasertib']"
72,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN frameshift variants', 'PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
73,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN splice site variants', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
74,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN splice site variants', 'PR positive', 'HER2-negative']","['Fulvestrant', 'Capivasertib']"
75,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN splice site variants', 'PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']"
76,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive', 'PTEN deletion']","['Fulvestrant', 'Capivasertib']"
77,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'PTEN deletion']","['Fulvestrant', 'Capivasertib']"
78,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive', 'PTEN deletion']","['Fulvestrant', 'Capivasertib']"
79,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['MET Exon 14 (Splice Site)'],['Capmatinib']
80,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['MET Exon 14 (Deletion)'],['Capmatinib']
81,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK', 'Wild type ROS1']","['Carboplatin', 'Cemiplimab', 'Pemetrexed']"
82,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['dMMR', 'Wild type EGFR', 'Wild type ALK', 'PD-L1 >= 50%']",['Cemiplimab']
83,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Ceritinib']
84,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,"['EGFR positive', 'Wild type KRAS']","['Fluorouracil', 'Irinotecan', 'Cetuximab']"
85,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,"['EGFR positive', 'Wild type KRAS']","['Irinotecan', 'Cetuximab']"
86,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,"['EGFR positive', 'Wild type KRAS']",['Cetuximab']
87,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,['BRAF p.V600E'],"['Cetuximab', 'Encorafenib']"
88,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Vemurafenib', 'Cobimetinib']"
89,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Vemurafenib', 'Cobimetinib']"
90,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Crizotinib']
91,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ROS1'],['Crizotinib']
92,Anaplastic Large Cell Lymphoma,anaplastic large cell lymphoma (ALCL),anaplastic large cell lymphoma,['v::ALK'],['Crizotinib']
93,Inflammatory Myofibroblastic Tumor,"unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT)","unresectable, recurrent, or refractory inflammatory myofibroblastic tumor",['v::ALK'],['Crizotinib']
94,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],['Dabrafenib']
95,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
96,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Trametinib', 'Dabrafenib']"
97,Melanoma,melanoma,melanoma,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
98,Melanoma,melanoma,melanoma,['BRAF p.V600K'],"['Trametinib', 'Dabrafenib']"
99,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Abemaciclib', 'Letrozole']"
100,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
101,Anaplastic Thyroid Cancer,locally advanced or metastatic anaplastic thyroid cancer (ATC),locally advanced or metastatic anaplastic thyroid cancer,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
102,Any solid tumor,unresectable or metastatic solid tumors,unresectable or metastatic any solid tumor,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
103,"Low-Grade Glioma, NOS",low-grade glioma (LGG),"low-grade glioma, nos",['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
104,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Dacomitinib']
105,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.L858R'],['Dacomitinib']
106,Chronic Myelogenous Leukemia,philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Dasatinib']
107,"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML),"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Dasatinib']
108,Chronic Myelogenous Leukemia,"chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML","chronic, accelerated, or myeloid or lymphoid blast phase ph+ chronic myelogenous leukemia",['BCR::ABL1'],['Dasatinib']
109,"Chronic Myeloid Leukemia, BCR-ABL1+","chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML","chronic, accelerated, or myeloid or lymphoid blast phase ph+ chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Dasatinib']
110,Acute Lymphoid Leukemia,philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL),philadelphia chromosome-positive acute lymphoid leukemia,['BCR::ABL1'],['Dasatinib']
111,Chronic Myelogenous Leukemia,philadelphia chromosome-positive CML,philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Dasatinib']
112,"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive CML,"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Dasatinib']
113,Acute Lymphoid Leukemia,philadelphia chromosome-positive ALL,philadelphia chromosome-positive acute lymphoid leukemia,['BCR::ABL1'],['Dasatinib']
114,Endometrial Carcinoma,primary advanced or recurrent endometrial cancer,primary advanced or recurrent endometrial carcinoma,['dMMR'],"['Carboplatin', 'Dostarlimab', 'Paclitaxel']"
115,Endometrial Carcinoma,primary advanced or recurrent endometrial cancer,primary advanced or recurrent endometrial carcinoma,['MSI-H'],"['Carboplatin', 'Dostarlimab', 'Paclitaxel']"
116,Endometrial Carcinoma,recurrent or advanced endometrial cancer,recurrent or advanced endometrial carcinoma,['dMMR'],['Dostarlimab']
117,Any solid tumor,recurrent or advanced solid tumors,recurrent or advanced any solid tumor,['dMMR'],['Dostarlimab']
118,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Pemetrexed']"
119,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Durvalumab', 'Pemetrexed', 'Cisplatin']"
120,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Gemcitabine']"
121,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Durvalumab', 'Gemcitabine', 'Cisplatin']"
122,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Nab-paclitaxel']"
123,Endometrial Carcinoma,primary advanced or recurrent endometrial cancer,primary advanced or recurrent endometrial carcinoma,['dMMR'],"['Carboplatin', 'Paclitaxel', 'Durvalumab']"
124,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['ESR1 oncogenic variants', 'HER2-negative', 'ER positive']",['Elacestrant']
125,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R140Q'],['Enasidenib']
126,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R140L'],['Enasidenib']
127,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R140G'],['Enasidenib']
128,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R140W'],['Enasidenib']
129,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R172K'],['Enasidenib']
130,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R172M'],['Enasidenib']
131,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R172G'],['Enasidenib']
132,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R172S'],['Enasidenib']
133,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R172W'],['Enasidenib']
134,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Binimetinib', 'Encorafenib']"
135,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Binimetinib', 'Encorafenib']"
136,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,['BRAF p.V600E'],"['Cetuximab', 'Encorafenib']"
137,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['BRAF p.V600E'],"['Binimetinib', 'Encorafenib']"
138,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ROS1'],['Entrectinib']
139,Any solid tumor,solid tumors,any solid tumor,['v::NTRK1'],['Entrectinib']
140,Any solid tumor,solid tumors,any solid tumor,['v::NTRK2'],['Entrectinib']
141,Any solid tumor,solid tumors,any solid tumor,['v::NTRK3'],['Entrectinib']
142,Bladder Urothelial Carcinoma,locally advanced or metastatic urothelial carcinoma (mUC),locally advanced or metastatic bladder urothelial carcinoma,['FGFR3 p.R248C'],['Erdafitinib']
143,Bladder Urothelial Carcinoma,locally advanced or metastatic urothelial carcinoma (mUC),locally advanced or metastatic bladder urothelial carcinoma,['FGFR3 p.S249C'],['Erdafitinib']
144,Bladder Urothelial Carcinoma,locally advanced or metastatic urothelial carcinoma (mUC),locally advanced or metastatic bladder urothelial carcinoma,['FGFR3 p.G370C'],['Erdafitinib']
145,Bladder Urothelial Carcinoma,locally advanced or metastatic urothelial carcinoma (mUC),locally advanced or metastatic bladder urothelial carcinoma,['FGFR3 p.Y373C'],['Erdafitinib']
146,Bladder Urothelial Carcinoma,locally advanced or metastatic urothelial carcinoma (mUC),locally advanced or metastatic bladder urothelial carcinoma,['FGFR3::TACC3'],['Erdafitinib']
147,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Erlotinib']
148,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.L858R'],['Erlotinib']
149,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Exemestane', 'Everolimus']"
150,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Exemestane', 'Everolimus']"
151,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Exemestane', 'Everolimus']"
152,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['HER2-negative', 'ER positive']",['Fulvestrant']
153,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'HER2-negative']",['Fulvestrant']
154,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']",['Fulvestrant']
155,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,['ER positive'],['Fulvestrant']
156,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,['PR positive'],['Fulvestrant']
157,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'ER positive']",['Fulvestrant']
158,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Ribociclib']"
159,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Ribociclib']"
160,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Ribociclib']"
161,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Palbociclib']"
162,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Palbociclib']"
163,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Palbociclib']"
164,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Abemaciclib']"
165,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Abemaciclib']"
166,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Abemaciclib']"
167,Intrahepatic Cholangiocarcinoma,"unresectable, locally or metastatic intrahepatic cholangiocarcinoma","unresectable, locally or metastatic intrahepatic cholangiocarcinoma",['FGFR2::v'],['Futibatinib']
168,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Gefitinib']
169,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.L858R'],['Gefitinib']
170,Acute Lymphoid Leukemia,acute myeloid leukemia,acute lymphoid leukemia,['CD33 +'],['Gemtuzumab ozogamicin']
171,Acute Lymphoid Leukemia,acute myeloid leukemia,acute lymphoid leukemia,['CD33 +'],['Gemtuzumab ozogamicin']
172,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3-ITD'],['Gilteritinib']
173,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835Y'],['Gilteritinib']
174,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835A'],['Gilteritinib']
175,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835E'],['Gilteritinib']
176,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835H'],['Gilteritinib']
177,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835N'],['Gilteritinib']
178,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835S'],['Gilteritinib']
179,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835V'],['Gilteritinib']
180,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myeloid leukemia,philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Imatinib']
181,"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive chronic myeloid leukemia,"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Imatinib']
182,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myeloid leukemia,philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Imatinib']
183,"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive chronic myeloid leukemia,"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Imatinib']
184,Acute Lymphoid Leukemia,philadelphia chromosome-positive acute lymphoblastic leukemia,philadelphia chromosome-positive acute lymphoid leukemia,['BCR::ABL1'],['Imatinib']
185,Acute Lymphoid Leukemia,philadelphia chromosome-positive acute lymphoblastic leukemia,philadelphia chromosome-positive acute lymphoid leukemia,['BCR::ABL1'],['Imatinib']
186,Myelodysplastic Syndromes,myelodyplastic/myeloproliferative diseases (MDS/MPD),myelodysplastic syndromes,['PDGFRA rearrangements'],['Imatinib']
187,Myelodysplastic Syndromes,myelodyplastic/myeloproliferative diseases (MDS/MPD),myelodysplastic syndromes,['PDGFRB rearrangements'],['Imatinib']
188,Aggressive Systemic Mastocytosis,aggressive systemic mastocytosis (ASM),aggressive systemic mastocytosis,['KIT p.D816V'],['Imatinib']
189,"Chronic Eosinophilic Leukemia, NOS",hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL),"chronic eosinophilic leukemia, nos",['FIP1L1::PDGFRA'],['Imatinib']
190,Gastrointestinal Stromal Tumor,unresectable and/or metastatic maligant gastrointestinal stromal tumors (GIST),unresectable and/or metastatic maligant gastrointestinal stromal tumor,['CD117 +'],['Imatinib']
191,Gastrointestinal Stromal Tumor,GIST,gastrointestinal stromal tumor,['FIP1L1::PDGFRA'],['Imatinib']
192,Cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,['FGFR2::v'],['Infigratinib']
193,Acute Lymphoid Leukemia,B-cell precursor acute lymphoblastic leukemia (ALL),b-cell precursor acute lymphoid leukemia,['CD22 +'],['Inotuzumab ozogamicin']
194,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,['MSI-H'],"['Nivolumab', 'Ipilimumab']"
195,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,['dMMR'],"['Nivolumab', 'Ipilimumab']"
196,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK', 'PD-L1 >= 1%']","['Nivolumab', 'Ipilimumab']"
197,Non-Small Cell Lung Cancer,metastatic or recurrent non-small cell lung cancer,metastatic or recurrent non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Nivolumab', 'Ipilimumab', 'Pemetrexed']"
198,Non-Small Cell Lung Cancer,metastatic or recurrent non-small cell lung cancer,metastatic or recurrent non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Nivolumab', 'Ipilimumab', 'Pemetrexed', 'Cisplatin']"
199,Non-Small Cell Lung Cancer,metastatic or recurrent non-small cell lung cancer,metastatic or recurrent non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Nivolumab', 'Ipilimumab']"
200,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132C'],['Ivosidenib']
201,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132G'],['Ivosidenib']
202,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132H'],['Ivosidenib']
203,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132L'],['Ivosidenib']
204,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132S'],['Ivosidenib']
205,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132C'],"['Ivosidenib', 'Azacitidine']"
206,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132G'],"['Ivosidenib', 'Azacitidine']"
207,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132H'],"['Ivosidenib', 'Azacitidine']"
208,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132L'],"['Ivosidenib', 'Azacitidine']"
209,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132S'],"['Ivosidenib', 'Azacitidine']"
210,Acute Myeloid Leukemia,relapsed or refractory AML,relapsed or refractory acute myeloid leukemia,['IDH1 p.R132C'],['Ivosidenib']
211,Acute Myeloid Leukemia,relapsed or refractory AML,relapsed or refractory acute myeloid leukemia,['IDH1 p.R132G'],['Ivosidenib']
212,Acute Myeloid Leukemia,relapsed or refractory AML,relapsed or refractory acute myeloid leukemia,['IDH1 p.R132H'],['Ivosidenib']
213,Acute Myeloid Leukemia,relapsed or refractory AML,relapsed or refractory acute myeloid leukemia,['IDH1 p.R132L'],['Ivosidenib']
214,Acute Myeloid Leukemia,relapsed or refractory AML,relapsed or refractory acute myeloid leukemia,['IDH1 p.R132S'],['Ivosidenib']
215,Myelodysplastic Syndromes,relapsed or refractory myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,['IDH1 p.R132C'],['Ivosidenib']
216,Myelodysplastic Syndromes,relapsed or refractory myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,['IDH1 p.R132G'],['Ivosidenib']
217,Myelodysplastic Syndromes,relapsed or refractory myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,['IDH1 p.R132H'],['Ivosidenib']
218,Myelodysplastic Syndromes,relapsed or refractory myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,['IDH1 p.R132L'],['Ivosidenib']
219,Myelodysplastic Syndromes,relapsed or refractory myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,['IDH1 p.R132S'],['Ivosidenib']
220,Cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,['IDH1 p.R132C'],['Ivosidenib']
221,Cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,['IDH1 p.R132G'],['Ivosidenib']
222,Cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,['IDH1 p.R132H'],['Ivosidenib']
223,Cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,['IDH1 p.R132L'],['Ivosidenib']
224,Cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,['IDH1 p.R132S'],['Ivosidenib']
225,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,['HER2-positive'],"['Lapatinib', 'Capecitabine']"
226,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-positive', 'ER positive']","['Lapatinib', 'Letrozole']"
227,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-positive', 'PR positive']","['Lapatinib', 'Letrozole']"
228,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-positive', 'PR positive', 'ER positive']","['Lapatinib', 'Letrozole']"
229,Any solid tumor,solid tumors,any solid tumor,['v::NTRK1'],['Larotrectinib']
230,Any solid tumor,solid tumors,any solid tumor,['v::NTRK2'],['Larotrectinib']
231,Any solid tumor,solid tumors,any solid tumor,['v::NTRK3'],['Larotrectinib']
232,Myelodysplastic Syndromes,transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS),transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes,['5q deletion'],['Lenalidomide']
233,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Lorlatinib']
234,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Margetuximab', 'Capecitabine']"
235,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Eribulin', 'Margetuximab']"
236,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Margetuximab', 'Gemcitabine']"
237,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Margetuximab', 'Vinorelbine']"
238,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3-ITD'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
239,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835Y'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
240,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835A'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
241,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835E'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
242,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835H'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
243,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835N'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
244,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835S'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
245,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835V'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
246,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.I836del'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
247,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['CDK12 oncogenic variants'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']"
248,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 20 (Insertion)'],['Mobocertinib']
249,Invasive Breast Carcinoma,early-stage breast cancer,early-stage invasive breast carcinoma,['HER2-positive'],['Neratinib']
250,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,['HER2-positive'],"['Capecitabine', 'Neratinib']"
251,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myeloid (Ph+ CML),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Nilotinib']
252,"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive chronic myeloid (Ph+ CML),"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Nilotinib']
253,Chronic Myelogenous Leukemia,chronic phase or accelerated phase Ph+ CML,chronic phase or accelerated phase ph+ chronic myelogenous leukemia,['BCR::ABL1'],['Nilotinib']
254,"Chronic Myeloid Leukemia, BCR-ABL1+",chronic phase or accelerated phase Ph+ CML,"chronic phase or accelerated phase ph+ chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Nilotinib']
255,Ovarian Epithelial Tumor,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent ovarian epithelial tumor,['BRCA1 pathogenic variants'],['Niraparib']
256,Ovarian Epithelial Tumor,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent ovarian epithelial tumor,['BRCA2 pathogenic variants'],['Niraparib']
257,High-Grade Serous Fallopian Tube Cancer,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent high-grade serous fallopian tube cancer,['BRCA1 pathogenic variants'],['Niraparib']
258,High-Grade Serous Fallopian Tube Cancer,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent high-grade serous fallopian tube cancer,['BRCA2 pathogenic variants'],['Niraparib']
259,Peritoneal Serous Carcinoma,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent peritoneal serous carcinoma,['BRCA1 pathogenic variants'],['Niraparib']
260,Peritoneal Serous Carcinoma,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent peritoneal serous carcinoma,['BRCA2 pathogenic variants'],['Niraparib']
261,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Nivolumab']"
262,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['PD-L1 >= 1%'],"['Nivolumab', 'Ipilimumab']"
263,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA1 oncogenic variants'],['Olaparib']
264,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA1 pathogenic variants'],['Olaparib']
265,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA2 oncogenic variants'],['Olaparib']
266,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA2 pathogenic variants'],['Olaparib']
267,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA1 oncogenic variants'],['Olaparib']
268,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA1 pathogenic variants'],['Olaparib']
269,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA2 oncogenic variants'],['Olaparib']
270,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA2 pathogenic variants'],['Olaparib']
271,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA1 oncogenic variants'],['Olaparib']
272,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA1 pathogenic variants'],['Olaparib']
273,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA2 oncogenic variants'],['Olaparib']
274,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA2 pathogenic variants'],['Olaparib']
275,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA1 oncogenic variants'],"['Olaparib', 'Bevacizumab']"
276,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA1 pathogenic variants'],"['Olaparib', 'Bevacizumab']"
277,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA2 oncogenic variants'],"['Olaparib', 'Bevacizumab']"
278,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA2 pathogenic variants'],"['Olaparib', 'Bevacizumab']"
279,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['HRD'],"['Olaparib', 'Bevacizumab']"
280,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA1 oncogenic variants'],"['Olaparib', 'Bevacizumab']"
281,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA1 pathogenic variants'],"['Olaparib', 'Bevacizumab']"
282,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA2 oncogenic variants'],"['Olaparib', 'Bevacizumab']"
283,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA2 pathogenic variants'],"['Olaparib', 'Bevacizumab']"
284,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['HRD'],"['Olaparib', 'Bevacizumab']"
285,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA1 oncogenic variants'],"['Olaparib', 'Bevacizumab']"
286,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA1 pathogenic variants'],"['Olaparib', 'Bevacizumab']"
287,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA2 oncogenic variants'],"['Olaparib', 'Bevacizumab']"
288,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA2 pathogenic variants'],"['Olaparib', 'Bevacizumab']"
289,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['HRD'],"['Olaparib', 'Bevacizumab']"
290,Ovarian Epithelial Tumor,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed ovarian epithelial tumor,['BRCA1 oncogenic variants'],['Olaparib']
291,Ovarian Epithelial Tumor,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed ovarian epithelial tumor,['BRCA1 pathogenic variants'],['Olaparib']
292,Ovarian Epithelial Tumor,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed ovarian epithelial tumor,['BRCA2 oncogenic variants'],['Olaparib']
293,Ovarian Epithelial Tumor,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed ovarian epithelial tumor,['BRCA2 pathogenic variants'],['Olaparib']
294,High-Grade Serous Fallopian Tube Cancer,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed high-grade serous fallopian tube cancer,['BRCA1 oncogenic variants'],['Olaparib']
295,High-Grade Serous Fallopian Tube Cancer,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed high-grade serous fallopian tube cancer,['BRCA1 pathogenic variants'],['Olaparib']
296,High-Grade Serous Fallopian Tube Cancer,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed high-grade serous fallopian tube cancer,['BRCA2 oncogenic variants'],['Olaparib']
297,High-Grade Serous Fallopian Tube Cancer,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed high-grade serous fallopian tube cancer,['BRCA2 pathogenic variants'],['Olaparib']
298,Peritoneal Serous Carcinoma,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed peritoneal serous carcinoma,['BRCA1 oncogenic variants'],['Olaparib']
299,Peritoneal Serous Carcinoma,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed peritoneal serous carcinoma,['BRCA1 pathogenic variants'],['Olaparib']
300,Peritoneal Serous Carcinoma,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed peritoneal serous carcinoma,['BRCA2 oncogenic variants'],['Olaparib']
301,Peritoneal Serous Carcinoma,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed peritoneal serous carcinoma,['BRCA2 pathogenic variants'],['Olaparib']
302,Invasive Breast Carcinoma,high risk early breast cancer,high risk early invasive breast carcinoma,"['HER2-negative', 'BRCA1 pathogenic variants']",['Olaparib']
303,Invasive Breast Carcinoma,high risk early breast cancer,high risk early invasive breast carcinoma,"['HER2-negative', 'BRCA2 pathogenic variants']",['Olaparib']
304,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-negative', 'BRCA1 pathogenic variants']",['Olaparib']
305,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-negative', 'BRCA2 pathogenic variants']",['Olaparib']
306,Pancreatic Adenocarcinoma,metastatic pancreatic adenocarcinoma,metastatic pancreatic adenocarcinoma,['BRCA1 pathogenic variants'],['Olaparib']
307,Pancreatic Adenocarcinoma,metastatic pancreatic adenocarcinoma,metastatic pancreatic adenocarcinoma,['BRCA2 pathogenic variants'],['Olaparib']
308,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
309,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 oncogenic variants'],['Olaparib']
310,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 pathogenic variants'],['Olaparib']
311,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 oncogenic variants'],['Olaparib']
312,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 pathogenic variants'],['Olaparib']
313,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATM pathogenic variants'],['Olaparib']
314,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATM oncogenic variants'],['Olaparib']
315,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BARD1 pathogenic variants'],['Olaparib']
316,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BARD1 oncogenic variants'],['Olaparib']
317,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRIP1 oncogenic variants'],['Olaparib']
318,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRIP1 pathogenic variants'],['Olaparib']
319,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CDK12 pathogenic variants'],['Olaparib']
320,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CDK12 oncogenic variants'],['Olaparib']
321,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK1 pathogenic variants'],['Olaparib']
322,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK1 oncogenic variants'],['Olaparib']
323,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK2 pathogenic variants'],['Olaparib']
324,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK2 oncogenic variants'],['Olaparib']
325,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['FANCL pathogenic variants'],['Olaparib']
326,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['FANCL oncogenic variants'],['Olaparib']
327,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['PALB2 pathogenic variants'],['Olaparib']
328,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['PALB2 oncogenic variants'],['Olaparib']
329,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51B pathogenic variants'],['Olaparib']
330,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51B oncogenic variants'],['Talazoparib']
331,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51C pathogenic variants'],['Olaparib']
332,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51C oncogenic variants'],['Olaparib']
333,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51D pathogenic variants'],['Olaparib']
334,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51D oncogenic variants'],['Olaparib']
335,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD54L pathogenic variants'],['Olaparib']
336,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD54L oncogenic variants'],['Olaparib']
337,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 oncogenic variants'],"['Prednisolone', 'Olaparib', 'Abiraterone acetate']"
338,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 pathogenic variants'],"['Prednisolone', 'Olaparib', 'Abiraterone acetate']"
339,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 oncogenic variants'],"['Prednisolone', 'Olaparib', 'Abiraterone acetate']"
340,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 pathogenic variants'],"['Prednisolone', 'Olaparib', 'Abiraterone acetate']"
341,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 oncogenic variants'],"['Prednisone', 'Olaparib', 'Abiraterone acetate']"
342,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 pathogenic variants'],"['Prednisone', 'Olaparib', 'Abiraterone acetate']"
343,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 oncogenic variants'],"['Prednisone', 'Olaparib', 'Abiraterone acetate']"
344,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 pathogenic variants'],"['Prednisone', 'Olaparib', 'Abiraterone acetate']"
345,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH1 p.R132C'],['Olutasidenib']
346,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH1 p.R132G'],['Olutasidenib']
347,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH1 p.R132H'],['Olutasidenib']
348,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH1 p.R132L'],['Olutasidenib']
349,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH1 p.R132S'],['Olutasidenib']
350,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Osimertinib']
351,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.L858R'],['Osimertinib']
352,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.L858R'],['Osimertinib']
353,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Osimertinib']
354,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR p.L858R'],"['Osimertinib', 'Pemetrexed', 'Cisplatin']"
355,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR p.L858R'],"['Carboplatin', 'Osimertinib', 'Pemetrexed']"
356,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Carboplatin', 'Osimertinib', 'Pemetrexed']"
357,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Osimertinib', 'Pemetrexed', 'Cisplatin']"
358,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.T790M'],['Osimertinib']
359,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Palbociclib', 'Letrozole']"
360,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Palbociclib', 'Letrozole']"
361,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Palbociclib', 'Letrozole']"
362,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Palbociclib']"
363,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Palbociclib']"
364,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Palbociclib']"
365,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,"['Wild type KRAS', 'Wild type HRAS']","['Panitumumab', 'Oxaliplatin', 'Fluorouracil']"
366,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,"['Wild type KRAS', 'Wild type HRAS']",['Panitumumab']
367,Non-Small Cell Lung Cancer,metastatic non-squamous non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Pemetrexed', 'Pembrolizumab']"
368,Non-Small Cell Lung Cancer,metastatic non-squamous non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Pemetrexed', 'Cisplatin', 'Pembrolizumab']"
369,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK', 'PD-L1 >= 1%']",['Pembrolizumab']
370,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['PD-L1 >= 1%'],['Pembrolizumab']
371,Head and Neck Squamous Cell Carcinoma,"metastatic or unresectable, recurrent HNSCC","metastatic or unresectable, recurrent head and neck squamous cell carcinoma",['PD-L1 (CPS) >= 1'],['Pembrolizumab']
372,Any solid tumor,unresectable or metastatic ... solid tumors,unresectable or metastatic any solid tumor,['dMMR'],['Pembrolizumab']
373,Any solid tumor,unresectable or metastatic ... solid tumors,unresectable or metastatic any solid tumor,['MSI-H'],['Pembrolizumab']
374,Colorectal Adenocarcinoma,unresectable or metastatic ... colorectal cancer,unresectable or metastatic colorectal adenocarcinoma,['dMMR'],['Pembrolizumab']
375,Colorectal Adenocarcinoma,unresectable or metastatic ... colorectal cancer,unresectable or metastatic colorectal adenocarcinoma,['MSI-H'],['Pembrolizumab']
376,Adenocarcinoma of the Gastroesophageal Junction,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocracinoma,locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction,"['HER2-positive', 'PD-L1 (CPS) >= 1']","['Trastuzumab', 'Fluorouracil', 'Cisplatin', 'Pembrolizumab']"
377,Adenocarcinoma of the Gastroesophageal Junction,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocracinoma,locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction,"['HER2-positive', 'PD-L1 (CPS) >= 1']","['Trastuzumab', 'Oxaliplatin', 'Capecitabine', 'Pembrolizumab']"
378,Adenocarcinoma of the Gastroesophageal Junction,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocarcinoma,locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction,['HER2-negative'],"['Fluorouracil', 'Cisplatin', 'Pembrolizumab']"
379,Adenocarcinoma of the Gastroesophageal Junction,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocarcinoma,locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction,['HER2-negative'],"['Oxaliplatin', 'Capecitabine', 'Pembrolizumab']"
380,Adenocarcinoma of the Gastroesophageal Junction,locally advanced or metastatic esophageal or gastroesophageal junction carcinoma,locally advanced or metastatic adenocarcinoma of the gastroesophageal junction,['PD-L1 (CPS) >= 10'],['Pembrolizumab']
381,Esophageal Adenocarcinoma,locally advanced or metastatic esophageal or gastroesophageal junction carcinoma,locally advanced or metastatic esophageal adenocarcinoma,['PD-L1 (CPS) >= 10'],['Pembrolizumab']
382,Cervical Adenocarcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical adenocarcinoma",['PD-L1 (CPS) >= 1'],"['Paclitaxel', 'Cisplatin', 'Pembrolizumab']"
383,Cervical Squamous Cell Carcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical squamous cell carcinoma",['PD-L1 (CPS) >= 1'],"['Paclitaxel', 'Cisplatin', 'Pembrolizumab']"
384,Cervical Adenocarcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical adenocarcinoma",['PD-L1 (CPS) >= 1'],"['Paclitaxel', 'Bevacizumab', 'Cisplatin', 'Pembrolizumab']"
385,Cervical Squamous Cell Carcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical squamous cell carcinoma",['PD-L1 (CPS) >= 1'],"['Paclitaxel', 'Bevacizumab', 'Cisplatin', 'Pembrolizumab']"
386,Cervical Adenocarcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical adenocarcinoma",['PD-L1 (CPS) >= 1'],"['Carboplatin', 'Paclitaxel', 'Pembrolizumab']"
387,Cervical Squamous Cell Carcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical squamous cell carcinoma",['PD-L1 (CPS) >= 1'],"['Carboplatin', 'Paclitaxel', 'Pembrolizumab']"
388,Cervical Adenocarcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical adenocarcinoma",['PD-L1 (CPS) >= 1'],"['Carboplatin', 'Paclitaxel', 'Bevacizumab', 'Pembrolizumab']"
389,Cervical Squamous Cell Carcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical squamous cell carcinoma",['PD-L1 (CPS) >= 1'],"['Carboplatin', 'Paclitaxel', 'Bevacizumab', 'Pembrolizumab']"
390,Cervical Adenocarcinoma,recurrent or metastatic cervical cancer,recurrent or metastatic cervical adenocarcinoma,['PD-L1 (CPS) >= 1'],['Pembrolizumab']
391,Cervical Squamous Cell Carcinoma,recurrent or metastatic cervical cancer,recurrent or metastatic cervical squamous cell carcinoma,['PD-L1 (CPS) >= 1'],['Pembrolizumab']
392,Endometrial Carcinoma,advanced endometrial carcinoma,advanced endometrial carcinoma,['MSI-L'],"['Lenvatinib', 'Pembrolizumab']"
393,Endometrial Carcinoma,advanced endometrial carcinoma,advanced endometrial carcinoma,['pMMR'],['Pembrolizumab']
394,Endometrial Carcinoma,advanced endometrial carcinoma,advanced endometrial carcinoma,['MSI-H'],['Pembrolizumab']
395,Any solid tumor,unresectable or metastatic ... solid tumors,unresectable or metastatic any solid tumor,['TMB-H (>= 10 mutations / Mb)'],['Pembrolizumab']
396,Invasive Breast Carcinoma,high-risk early-stage triple-negative breast cancer,high-risk early-stage triple-negative invasive breast carcinoma,"['ER negative', 'PR negative', 'HER2-negative']","['Carboplatin', 'Doxorubicin', 'Paclitaxel', 'Cyclophosphamide', 'Pembrolizumab']"
397,Invasive Breast Carcinoma,locally recurrent unresectable or metastatic triple-negative breast cancer,locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma,"['ER negative', 'PR negative', 'HER2-negative', 'PD-L1 (CPS) >= 10']","['Paclitaxel', 'Pembrolizumab']"
398,Invasive Breast Carcinoma,locally recurrent unresectable or metastatic triple-negative breast cancer,locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma,"['ER negative', 'PR negative', 'HER2-negative', 'PD-L1 (CPS) >= 10']","['Carboplatin', 'Gemcitabine', 'Pembrolizumab']"
399,Cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,['FGFR2::v'],['Pemigatinib']
400,Cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,['FGFR2 rearrangements'],['Pemigatinib']
401,Myeloid/Lymphoid Neoplasms,relapsed or refractory myeloid/lymphoid neoplasms (MLNs),relapsed or refractory myeloid/lymphoid neoplasms,['FGFR1 rearrangements'],['Pemigatinib']
402,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Docetaxel', 'Pertuzumab']"
403,Invasive Breast Carcinoma,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)","locally advanced, inflammatory, or early stage invasive breast carcinoma",['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']"
404,Invasive Breast Carcinoma,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)","locally advanced, inflammatory, or early stage invasive breast carcinoma",['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
405,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Docetaxel', 'Pertuzumab']"
406,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Paclitaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
407,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Cyclophosphamide']"
408,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Fluorouracil', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']"
409,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
410,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Paclitaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
411,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Docetaxel', 'Pertuzumab', 'Cyclophosphamide']"
412,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
413,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Carboplatin', 'Docetaxel', 'Pertuzumab']"
414,Invasive Breast Carcinoma,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)","locally advanced, inflammatory, or early stage invasive breast carcinoma",['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']"
415,Invasive Breast Carcinoma,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)","locally advanced, inflammatory, or early stage invasive breast carcinoma",['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
416,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Carboplatin', 'Docetaxel', 'Pertuzumab']"
417,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Paclitaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
418,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Cyclophosphamide']"
419,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Fluorouracil', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']"
420,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
421,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Paclitaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
422,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Docetaxel', 'Pertuzumab', 'Cyclophosphamide']"
423,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']"
424,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']"
425,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']"
426,Acute Lymphoid Leukemia,Ph+ ALL,acute lymphoid leukemia,['BCR::ABL1'],"['Prednisone', 'Ponatinib', 'Vincristine', 'Methotrexate', 'Cytarabine']"
427,Acute Lymphoid Leukemia,Ph+ ALL,acute lymphoid leukemia,"['ABL1 p.T315I', 'BCR::ABL1']",['Ponatinib']
428,Chronic Myelogenous Leukemia,CML,chronic myelogenous leukemia,['ABL1 p.T315I'],['Ponatinib']
429,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['v::RET'],['Pralsetinib']
430,Papillary Thyroid Cancer,advanced or metastatic... thyroid cancer,advanced or metastatic papillary thyroid cancer,['v::RET'],['Pralsetinib']
431,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Erlotinib', 'Ramucirumab']"
432,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.L858R'],"['Erlotinib', 'Ramucirumab']"
433,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['v::ROS1'],['Repotrectinib']
434,Any solid tumor,solid tumors,any solid tumor,['v::NTRK1'],['Repotrectinib']
435,Any solid tumor,solid tumors,any solid tumor,['v::NTRK2'],['Repotrectinib']
436,Any solid tumor,solid tumors,any solid tumor,['v::NTRK3'],['Repotrectinib']
437,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Anastrozole', 'Ribociclib']"
438,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Anastrozole', 'Ribociclib']"
439,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Anastrozole', 'Ribociclib']"
440,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Ribociclib', 'Letrozole']"
441,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Ribociclib', 'Letrozole']"
442,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Ribociclib', 'Letrozole']"
443,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Ribociclib']"
444,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Ribociclib']"
445,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Ribociclib']"
446,Non-Hodgkin Lymphoma,B-cell Non-Hodgkin's Lymphoma (NHL),b-cell non-hodgkin lymphoma,['CD20 +'],['Rituximab']
447,Non-Hodgkin Lymphoma,B-cell Non-Hodgkin's Lymphoma (NHL),b-cell non-hodgkin lymphoma,['CD20 +'],"['Prednisolone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']"
448,Non-Hodgkin Lymphoma,B-cell Non-Hodgkin's Lymphoma (NHL),b-cell non-hodgkin lymphoma,['CD20 +'],"['Doxorubicin', 'Prednisolone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']"
449,Non-Hodgkin Lymphoma,B-cell Non-Hodgkin's Lymphoma (NHL),b-cell non-hodgkin lymphoma,['CD20 +'],"['Rituximab', 'Mitoxantrone', 'Fludarabine', 'Cyclophosphamide']"
451,Non-Hodgkin Lymphoma,Non-Hodgkin's Lymphoma (NHL),non-hodgkin lymphoma,['CD20 +'],"['Doxorubicin', 'Prednisone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']"
452,Non-Hodgkin Lymphoma,diffuse large B-cell Non-Hodgkin's Lymhpoma (NHL),diffuse large b-cell non-hodgkin lymphoma,['CD20 +'],"['Doxorubicin', 'Prednisone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']"
453,Diffuse Large B-Cell Lymphoma,"mature B-cell NHL and mature B-cell acute leukemia (B-AL) previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)","previously untreated, advanced stage, cd20-positive diffuse large b-cell lymphoma",['CD20 +'],"['Doxorubicin', 'Prednisone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']"
454,Burkitt Lymphoma,"mature B-cell NHL and mature B-cell acute leukemia (B-AL) previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)","previously untreated, advanced stage, cd20-positive burkitt lymphoma",['CD20 +'],"['Doxorubicin', 'Prednisone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']"
455,Mature B-Cell Neoplasms,"mature B-cell NHL and mature B-cell acute leukemia (B-AL) previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)","previously untreated, advanced stage, cd20-positive mature b-cell neoplasms",['CD20 +'],"['Doxorubicin', 'Prednisone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']"
456,Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leuekmia (CLL),chronic lymphocytic leukemia,['CD20 +'],"['Rituximab', 'Fludarabine', 'Cyclophosphamide']"
457,Ovarian Epithelial Tumor,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",ovarian epithelial tumor,['BRCA1 oncogenic variants'],['Rucaparib']
458,Ovarian Epithelial Tumor,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",ovarian epithelial tumor,['BRCA1 pathogenic variants'],['Rucaparib']
459,Ovarian Epithelial Tumor,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",ovarian epithelial tumor,['BRCA2 oncogenic variants'],['Rucaparib']
460,Ovarian Epithelial Tumor,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",ovarian epithelial tumor,['BRCA2 pathogenic variants'],['Rucaparib']
461,High-Grade Serous Fallopian Tube Cancer,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",high-grade serous fallopian tube cancer,['BRCA1 oncogenic variants'],['Rucaparib']
462,High-Grade Serous Fallopian Tube Cancer,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",high-grade serous fallopian tube cancer,['BRCA1 pathogenic variants'],['Rucaparib']
463,High-Grade Serous Fallopian Tube Cancer,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",high-grade serous fallopian tube cancer,['BRCA2 oncogenic variants'],['Rucaparib']
464,High-Grade Serous Fallopian Tube Cancer,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",high-grade serous fallopian tube cancer,['BRCA2 pathogenic variants'],['Rucaparib']
465,Peritoneal Serous Carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",peritoneal serous carcinoma,['BRCA1 oncogenic variants'],['Rucaparib']
466,Peritoneal Serous Carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",peritoneal serous carcinoma,['BRCA1 pathogenic variants'],['Rucaparib']
467,Peritoneal Serous Carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",peritoneal serous carcinoma,['BRCA2 oncogenic variants'],['Rucaparib']
468,Peritoneal Serous Carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",peritoneal serous carcinoma,['BRCA2 pathogenic variants'],['Rucaparib']
469,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 oncogenic variants'],['Rucaparib']
470,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 pathogenic variants'],['Rucaparib']
471,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 oncogenic variants'],['Rucaparib']
472,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 pathogenic variants'],['Rucaparib']
473,Invasive Breast Carcinoma,unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC),unresectable locally advanced or metastatic triple-negative invasive breast carcinoma,"['ER negative', 'PR negative', 'HER2-negative']",['Sacituzumab govitecan']
474,Invasive Breast Carcinoma,locally advanced or metastatic ... breast cancer,locally advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']",['Sacituzumab govitecan']
475,Invasive Breast Carcinoma,locally advanced or metastatic ... breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']",['Sacituzumab govitecan']
476,Invasive Breast Carcinoma,locally advanced or metastatic ... breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']",['Sacituzumab govitecan']
477,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['v::RET'],['Selpercatinib']
478,Medullary Thyroid Cancer,advanced or metastatic medullary thyroid cancer,advanced or metastatic medullary thyroid cancer,['RET oncogenic variants'],['Selpercatinib']
479,Anaplastic Thyroid Cancer,advanced or metastatic thyroid cancer,advanced or metastatic anaplastic thyroid cancer,['v::RET'],['Selpercatinib']
480,Any solid tumor,locally advanced or metastatic solid tumors,locally advanced or metastatic any solid tumor,['v::RET'],['Selpercatinib']
481,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['KRAS p.G12C'],['Sotorasib']
482,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'BRCA1 pathogenic variants']",['Talazoparib']
483,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'BRCA2 pathogenic variants']",['Talazoparib']
484,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['MET Exon 14 (Splice Site)'],['Tepotinib']
485,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['MET Exon 14 (Deletion)'],['Tepotinib']
486,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],['Trametinib']
487,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],['Trametinib']
488,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
489,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Trametinib', 'Dabrafenib']"
490,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
491,Anaplastic Thyroid Cancer,locally advanced or metastatic anaplastic thyroid cancer,locally advanced or metastatic anaplastic thyroid cancer,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
492,Any solid tumor,unresectable or metastatic solid tumors,unresectable or metastatic any solid tumor,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
493,"Low-Grade Glioma, NOS",low-grade glioma (LGG),"low-grade glioma, nos",['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']"
494,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,['HER2-positive'],['Trastuzumab']
495,Gastrointestinal Stromal Tumor,metastatic gastric or gastroesophageal junction adenocarcinoma,metastatic gastrointestinal stromal tumor,['HER2-positive'],['Trastuzumab']
496,Invasive Breast Carcinoma,unresectable or metastatic breast cancer,unresectable or metastatic invasive breast carcinoma,['HER2-positive'],['Trastuzumab deruxtecan']
497,Invasive Breast Carcinoma,unresectable or metastatic ... breast cancer,unresectable or metastatic invasive breast carcinoma,['HER2-low'],['Trastuzumab deruxtecan']
498,Non-Small Cell Lung Cancer,unresectable or metastatic non-small cell lung cancer,unresectable or metastatic non-small cell lung cancer,['ERBB2 oncogenic variants'],['Trastuzumab deruxtecan']
499,Adenocarcinoma of the Gastroesophageal Junction,locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma,locally advanced or metastatic adenocarcinoma of the gastroesophageal junction,['HER2-positive'],['Trastuzumab deruxtecan']
500,Any solid tumor,unresectable or metastatic solid tumors,unresectable or metastatic any solid tumor,['HER2-positive'],['Trastuzumab deruxtecan']
501,Invasive Breast Carcinoma,advanced unresectable or metastatic breast cancer,unresectable or metastatic invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Capecitabine', 'Tucatinib']"
502,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],['Vemurafenib']
503,Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease,Erdheim-Chester Disease,non-langerhans cell histiocytosis/erdheim-chester disease,['BRAF p.V600E'],['Vemurafenib']
504,Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease,Erdheim-Chester Disease,non-langerhans cell histiocytosis/erdheim-chester disease,['BRAF p.V600K'],['Vemurafenib']
505,Follicular Lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.Y646N'],['Tazemetostat']
506,Follicular Lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.Y646F'],['Tazemetostat']
507,Follicular Lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.Y646H'],['Tazemetostat']
508,Follicular Lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.Y646S'],['Tazemetostat']
509,Follicular Lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.Y646C'],['Tazemetostat']
510,Follicular Lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.A862G'],['Tazemetostat']
511,Follicular Lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.A692V'],['Tazemetostat']
512,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
513,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
514,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
515,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATM pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
516,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATM oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
517,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATR oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
518,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CDK12 oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
519,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATR pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
520,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['FANCA oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
521,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK2 pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
522,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK2 oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
523,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['FANCA pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
524,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['MLH1 oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
525,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['PALB2 pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
526,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['PALB2 oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
527,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['MLH1 pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
528,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['MRE11 oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
529,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51C pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
530,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51C oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
531,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['MRE11 pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
532,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['NBN oncogenic variants'],"['Enzalutamide', 'Talazoparib']"
533,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['NBN pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
534,Renal Angiomyolipoma,renal angiomyolipoma,renal angiomyolipoma,['TSC1 oncogenic variants'],['Everolimus']
535,Renal Angiomyolipoma,renal angiomyolipoma,renal angiomyolipoma,['TSC2 oncogenic variants'],['Everolimus']
536,Anaplastic Thyroid Cancer,subependymal giant cell astrocytoma,anaplastic thyroid cancer,['TSC1 oncogenic variants'],['Everolimus']
537,Anaplastic Thyroid Cancer,subependymal giant cell astrocytoma,anaplastic thyroid cancer,['TSC2 oncogenic variants'],['Everolimus']
538,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CDK12 pathogenic variants'],"['Enzalutamide', 'Talazoparib']"
539,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Osimertinib']
540,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.L858R'],['Osimertinib']
541,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Amivantamab', 'Lazertinib']"
542,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR p.L858R'],"['Amivantamab', 'Lazertinib']"
543,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Amivantamab', 'Lazertinib']"
544,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.L858R'],"['Amivantamab', 'Lazertinib']"
545,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Carboplatin', 'Amivantamab', 'Pemetrexed']"
546,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.L858R'],"['Carboplatin', 'Amivantamab', 'Pemetrexed']"
547,Ovarian Epithelial Tumor,"epithelial ovarian, fallopian tube, or primary peritoneal",ovarian epithelial tumor,['FOLR1 positive'],['Mirvetuximab soravtansine']
548,High-Grade Serous Fallopian Tube Cancer,"epithelial ovarian, fallopian tube, or primary peritoneal",high-grade serous fallopian tube cancer,['FOLR1 positive'],['Mirvetuximab soravtansine']
549,Peritoneal Serous Carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal",peritoneal serous carcinoma,['FOLR1 positive'],['Mirvetuximab soravtansine']
550,"Low-Grade Glioma, NOS",low-grade glioma (LGG),"low-grade glioma, nos",['BRAF rearrangements'],['Tovorafenib']
551,"Low-Grade Glioma, NOS",low-grade glioma (LGG),"low-grade glioma, nos",['v::BRAF'],['Tovorafenib']
552,"Low-Grade Glioma, NOS",low-grade glioma (LGG),"low-grade glioma, nos",['BRAF p.V600E'],['Tovorafenib']
553,"Low-Grade Glioma, NOS",low-grade glioma (LGG),"low-grade glioma, nos",['BRAF p.V600K'],['Tovorafenib']
554,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Durvalumab']"
555,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Durvalumab', 'Gemcitabine', 'Cisplatin']"
556,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Durvalumab', 'Pemetrexed', 'Cisplatin']"
557,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Durvalumab', 'Pemetrexed']"
558,Colorectal Adenocarcinoma,colorectal cancer,colorectal adenocarcinoma,['KRAS p.G12C'],"['Adagrasib', 'Cetuximab']"
559,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH1 p.R132C'],['Vorasidenib']
560,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH1 p.R132G'],['Vorasidenib']
561,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH1 p.R132H'],['Vorasidenib']
562,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH1 p.R132L'],['Vorasidenib']
563,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH1 p.R132S'],['Vorasidenib']
564,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH2 p.R172K'],['Vorasidenib']
565,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH2 p.R172M'],['Vorasidenib']
566,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH2 p.R172G'],['Vorasidenib']
567,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH2 p.R172S'],['Vorasidenib']
568,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH2 p.R172W'],['Vorasidenib']
569,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH1 p.R132C'],['Vorasidenib']
570,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH1 p.R132G'],['Vorasidenib']
571,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH1 p.R132H'],['Vorasidenib']
572,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH1 p.R132L'],['Vorasidenib']
573,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH1 p.R132S'],['Vorasidenib']
574,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH2 p.R172K'],['Vorasidenib']
575,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH2 p.R172M'],['Vorasidenib']
576,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH2 p.R172G'],['Vorasidenib']
577,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH2 p.R172S'],['Vorasidenib']
578,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH2 p.R172W'],['Vorasidenib']
579,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Goserelin', 'Anastrozole', 'Ribociclib']"
580,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Goserelin', 'Anastrozole', 'Ribociclib']"
581,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Goserelin', 'Anastrozole', 'Ribociclib']"
582,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Goserelin', 'Ribociclib', 'Letrozole']"
583,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Goserelin', 'Ribociclib', 'Letrozole']"
584,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Goserelin', 'Ribociclib', 'Letrozole']"
585,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Nivolumab', 'Pemetrexed', 'Cisplatin']"
586,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Nivolumab', 'Gemcitabine', 'Cisplatin']"
587,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Nivolumab', 'Ipilimumab', 'Pemetrexed']"
588,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Nivolumab', 'Ipilimumab', 'Pemetrexed', 'Cisplatin']"
589,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Nivolumab', 'Ipilimumab']"
591,Colorectal Adenocarcinoma,colorectal cancer,colorectal adenocarcinoma,['dMMR'],"['Nivolumab', 'Ipilimumab']"
592,Colorectal Adenocarcinoma,colorectal cancer,colorectal adenocarcinoma,['MSI-H'],['Nivolumab']
593,Colorectal Adenocarcinoma,colorectal cancer,colorectal adenocarcinoma,['dMMR'],['Nivolumab']
594,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Inavolisib', 'Fulvestrant', 'Palbociclib']"
595,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'PIK3CA somatic variants']","['Inavolisib', 'Fulvestrant', 'Palbociclib']"
596,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Inavolisib', 'Fulvestrant', 'Palbociclib']"
597,Adenocarcinoma of the Gastroesophageal Junction,gastric or gastroesophageal junction adenocarcinoma,adenocarcinoma of the gastroesophageal junction,"['HER2-negative', 'CLDN18.2 >= 75%']","['Oxaliplatin', 'Fluorouracil', 'Zolbetuximab']"
598,Adenocarcinoma of the Gastroesophageal Junction,gastric or gastroesophageal junction adenocarcinoma,adenocarcinoma of the gastroesophageal junction,"['HER2-negative', 'CLDN18.2 >= 75%']","['Oxaliplatin', 'Zolbetuximab', 'Capecitabine']"
599,Intraductal Papillary Neoplasm of the Bile Duct,biliary tract cancer (BTC),intraductal papillary neoplasm of the bile duct,['HER2-positive'],['Zanidatamab']
600,Intracholecystic Papillary Neoplasm,biliary tract cancer (BTC),intracholecystic papillary neoplasm,['HER2-positive'],['Zanidatamab']
601,Cholangiocarcinoma,biliary tract cancer (BTC),cholangiocarcinoma,['HER2-positive'],['Zanidatamab']
602,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['v::NRG1'],['Zenocutuzumab']
603,Pancreatic Adenocarcinoma,pancreatic adenocarcinoma,pancreatic adenocarcinoma,['v::NRG1'],['Zenocutuzumab']
604,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['v::ALK'],['Ensartinib']
605,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,['BRAF p.V600E'],"['Oxaliplatin', 'Fluorouracil', 'Cetuximab', 'Encorafenib']"
606,"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Asciminib']
607,"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Asciminib']
608,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Pemetrexed']"
609,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Durvalumab', 'Pemetrexed', 'Cisplatin']"
610,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Gemcitabine']"
611,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Durvalumab', 'Gemcitabine', 'Cisplatin']"
612,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Nab-paclitaxel']"
613,Acute Lymphoid Leukemia,acute leukemia,acute lymphoid leukemia,['t(KMT2A;v)'],['Revumenib']
614,Acute Myeloid Leukemia,acute leukemia,acute myeloid leukemia,['t(KMT2A;v)'],['Revumenib']
615,Burkitt Lymphoma,acute leukemia,burkitt lymphoma,['t(KMT2A;v)'],['Revumenib']
616,Acute Leukemias of Ambiguous Lineage,acute leukemia,acute leukemias of ambiguous lineage,['t(KMT2A;v)'],['Revumenib']
617,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Abemaciclib', 'Letrozole']"
618,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Anastrozole', 'Abemaciclib']"
619,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Anastrozole', 'Abemaciclib']"
620,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Anastrozole', 'Abemaciclib']"
621,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Exemestane', 'Abemaciclib']"
622,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Exemestane', 'Abemaciclib']"
623,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Exemestane', 'Abemaciclib']"
624,Colorectal Adenocarcinoma,colorectal cancer,colorectal adenocarcinoma,['MSI-H'],"['Nivolumab', 'Ipilimumab']"
625,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['v::ROS1'],['Taletrectinib']
626,Lung Non-Squamous Non-Small Cell Carcinoma,non-squamous non-small cell lung cancer,lung non-squamous non-small cell carcinoma,['c-Met >= 50%'],['Telisotuzumab Vedotin']
627,Low-Grade Serous Ovarian Cancer,low-grade serous ovarian cancer (LGSOC),low-grade serous ovarian cancer,['KRAS p.G12C'],"['Avutometinib', 'Defactinib']"
628,Low-Grade Serous Ovarian Cancer,low-grade serous ovarian cancer (LGSOC),low-grade serous ovarian cancer,['KRAS p.G12V'],"['Avutometinib', 'Defactinib']"
629,APL with PML-RARA,low-risk acute promyelocytic leukemia (APL),low-risk apl with pml-rara,['t(15;17)'],['Arsenic trioxide']
630,APL with PML-RARA,acute promyelocytic leukemia (APL),apl with pml-rara,['t(15;17)'],['Arsenic trioxide']
631,Chronic Myelogenous Leukemia,Ph+ CML-CP and CML-AP,chronic myelogenous leukemia,['BCR::ABL1'],['Nilotinib']
632,"Chronic Myeloid Leukemia, BCR-ABL1+",Ph+ CML-CP and CML-AP,"chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Nilotinib']
634,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Asciminib']
635,Head and Neck Squamous Cell Carcinoma,head and neck squamous cell cancer,head and neck squamous cell carcinoma,['PD-L1 (CPS) >= 1'],['Pembrolizumab']
636,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR somatic variants'],['Datopotamab deruxtecan']
637,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Datopotamab deruxtecan']
638,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.L858R'],['Datopotamab deruxtecan']
639,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.T790M'],['Datopotamab deruxtecan']
640,Invasive Breast Carcinoma,non-small cell lung cancer,invasive breast carcinoma,['EGFR Exon 20 (Insertion)'],['Datopotamab deruxtecan']
641,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['HER2-negative', 'ER positive']",['Datopotamab deruxtecan']
642,Non-Small Cell Lung Cancer,breast cancer,non-small cell lung cancer,"['PR positive', 'HER2-negative']",['Datopotamab deruxtecan']
643,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']",['Datopotamab deruxtecan']
644,Non-Small Cell Lung Cancer,non-small cell lung cancer (NSCLC),non-small cell lung cancer,['EGFR Exon 20 (Insertion)'],['Sunvozertinib']
645,Lung Non-Squamous Non-Small Cell Carcinoma,non-squamous non-small cell lung cancer,lung non-squamous non-small cell carcinoma,['ERBB2 TKD activating variants'],['Zongertinib']
